Trial Profile
A randomized, double-blind, placebo-controlled study to investigate the effects of an 8-week recombinant human erythropoietin (NeoRecormon) treatment on well-trained cyclists and their cycling performance.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 May 2016
Price :
$35
*
At a glance
- Drugs Epoetin beta (Primary) ; Ascorbic acid
- Indications Anaemia
- Focus Pharmacodynamics
- 10 May 2016 New trial record